Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | KLK3 | P07288 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744791 | 0.75 | CYP2C9 (0.54) | CYP2C9CYP2C19CYP2D6CYP19A1TSHR | |
| SCHEMBL14844403 | 0.73 | KLK3 (0.34) | TRPM8KLK3CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5174261 | 0.70 | CYP2D6 (0.41) | CYP2C9CYP2C19CYP2D6CYP19A1PIM1 | |
| SCHEMBL1460033 | 0.69 | KLK3 (0.32) | KLK3CYP2C9CYP2C19CYP2D6CYP19A1 | |
| SCHEMBL28120845 | 0.68 | TRPM8 (0.42) | TRPM8CYP2C9CYP2C19CYP2D6CYP19A1 | |
| SCHEMBL78566 | 0.67 | NISCH (0.50) | CYP2C9CYP2C19CYP2D6CYP19A1TSHR | |
| SCHEMBL29598957 | 0.67 | NISCH (0.50) | CYP2C9CYP2C19CYP2D6CYP19A1TSHR | |
| SCHEMBL29454745 | 0.67 | NISCH (0.50) | CYP2C9CYP2C19CYP2D6CYP19A1TSHR | |
| SCHEMBL23400704 | 0.67 | MEN1 (0.49) | CYP2C9CYP2C19TSHRALDH1A1HDAC3 | |
| SCHEMBL14557175 | 0.66 | PIM1 (0.37) | KLK3CYP2C9CYP2C19CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092444-A1 | DIAZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092444-A1 | DIAZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | TRPM8 72/4885KLK3 4712/4885CYP2C9 2005/4885 |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | ORAI2, ORAI1, RYR2 | TRPM8 155/4885KLK3 4630/4885CYP2C9 2999/4885 |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | TRPM8 198/4885KLK3 4736/4885CYP2C9 3333/4885 |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | TRPM8 62/4885KLK3 4339/4885CYP2C9 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.